Ensuring Access to Clinical Trials

Recipients

  • Your Representative

Contact

*Required fields
 

If you take action and have not already registered, you will receive periodic updates and communications from Parent Project Muscular Dystrophy.

Message

Pass the Ensuring Access to Clinical Trials Act (H.R. 209/S. 139)!

Dear [Decision Maker],

My family urges you to pass the Ensuring Access to Clinical Trials Act of 2015 (H.R. 209/S. 139) to eliminate the sunset clause in the Improving Access to Clinical Trials Act of 2009 (IACT), which expires on October 5, 2015.

IACT, which was signed into law in 2010, allows patients with rare diseases to receive up to $2,000 in compensation for participating in clinical trials without that compensation counting as income when calculating eligibility for SSI and Medicaid. The Ensuring Access to Clinical Trials Act of 2015 simply makes IACT permanent, removing an enduring barrier to clinical research and allowing social security beneficiaries to participate in and benefit from clinical trials.

With IACT's expiration fewer than 30 days away, the Duchenne community needs your support for this critical piece of legislation. The Duchenne community has made major gains in the last 10 years and we don't want barriers like this to hamper that progress for patients. Please help pass this legislation.


Sincerely,
[Your Name]
[Your Address]
[City, State ZIP]
[Your Email]